At 3.0% CAGR, Middle East & Africa Infectious Disease Therapeutics Market is Projected to be Worth US$ 7,237.61 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa infectious disease therapeutics market was valued at US$ 5,722.81 million in 2022 and is projected to reach US$ 7,237.61 million by 2030, registering a CAGR of 3.0% from 2022 to 2030. Rising prevalence of infectious disease and escalating threat of antibiotic resistance are among the critical factors attributed to drive the Middle East & Africa infectious disease therapeutics market growth.

Research and development (R&D) is a critical part of the business of biopharmaceuticals and pharmaceutical companies. R&D enables them to launch new products for several therapeutic applications with significant medical and commercial potential. Also, leading market players are investing in R&D to develop enhanced technologies and gain more revenue share.

In 2023, a Memorandum of Understanding (MoU) between Emergex Vaccines and the Vaccine Industrial Company (VIC) aims to develop and commercialize immunological set-point candidates that prime T cells against treatments for infectious diseases. The GCC member nations (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates), as well as other designated regions and other Middle Eastern territories, were among the territories included in the agreement, in addition to Saudi Arabia. Also, in 2021, a new research fund was established by the Saudi Charity Community Jameel to fund joint research between King Abdulaziz University (KAU) in Saudi Arabia and Imperial College London, UK, in an effort to combat the global threat posed by infectious illnesses.

Thus, rising focus on R&D and funding in infectious disease therapeutics drive the infectious disease therapeutics market growth.

On the contrary, emergence of anti-infective drugs resistance and associated side effects hamper the growth of the Middle East & Africa infectious disease therapeutics market.

Based on drug class, the Middle East & Africa infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held 44.3% market share in 2022, amassing US$ 2,536.99 million. It is projected to garner US$ 3,236.88 million by 2030 to register 3.1% CAGR during 2022-2030.

In terms of indication, the Middle East & Africa infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV segment held 35.6% share of Middle East & Africa infectious disease therapeutics market in 2022, amassing US$ 2,035.52 million. It is anticipated to garner US$ 2,659.26 million by 2030 to expand at 3.4% CAGR during 2022-2030.

Based on route of administration, the Middle East & Africa infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held 55.5% market share in 2022, amassing US$ 3,177.31 million. It is projected to garner US$ 4,082.82 million by 2030 to register 3.2% CAGR during 2022-2030.

In terms of distribution channel, the Middle East & Africa infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held 49.1% share of Middle East & Africa infectious disease therapeutics market in 2022, amassing US$ 2,811.53 million. It is anticipated to garner US$ 3,642.23 million by 2030 to expand at 3.3% CAGR during 2022-2030.

Based on country, the Middle East & Africa infectious disease therapeutics market is categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 40.1% share of Middle East & Africa infectious disease therapeutics market in 2022. It was assessed at US$ 2,294.19 million in 2022 and is likely to hit US$ 2,851.82 million by 2030, registering a CAGR of 2.8% during 2022-2030.

Key players operating in the Middle East & Africa infectious disease therapeutics market are AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc, Merck & Co Inc, and Pfizer Inc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com